secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-039225
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences Q4 rev $57.5M (-1.3%); FY24 net loss $6.0M; guides FY25 rev $204-212M
--------------------------------------------------------------------------------

- Full year 2024 revenue $200.5M (+3.9% YoY); Q4 revenue $57.5M (-1.3% YoY, +1.4% constant currency).
- Net loss improved to $6.0M from $12.1M in 2023; adjusted EBITDA $22.4M (+77% YoY).
- Installed base reached 3,034 instruments; 667 placed in 2024.
- Board authorized new $50M stock repurchase program for 2025; $21.6M repurchased in 2024.
- 2025 revenue guidance $204-212M (2-6% growth); opened Singapore manufacturing facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525039225/0001193125-25-039225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525039225/d829130d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-039225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer